Wordt geladen...
ACR Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From the RAPID 1 Trial
OBJECTIVE: The ACR hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to ACR20/50/70 scores but has not been tested in clinical trials. We performed a post hoc analysis of a phase III study of certolizumab pegol (RAPID 1) using the ACR hybrid....
Bewaard in:
| Hoofdauteurs: | , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2011
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3016460/ https://ncbi.nlm.nih.gov/pubmed/20799264 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.20331 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|